Intest Res.  2014 Jul;12(3):176-177. 10.5217/ir.2014.12.3.176.

A High Risk Group in the Modified National Institutes of Health Consensus Criteria for the Gastrointestinal Stromal Tumor: A Clear Indication of the Adjuvant Imatinib

• Chang DK

• KMID: 2174375
• DOI: http://doi.org/10.5217/ir.2014.12.3.176

Abstract

No abstract available.

MeSH Terms

Consensus*
Gastrointestinal Stromal Tumors*
Imatinib Mesylate
National Institutes of Health (U.S.)*

Reference

1. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002; 33:459–465. PMID: 12094370.

2. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008; 39:1411–1419. PMID: 18774375.

3. Jang SH, Kwon JE, Kim JH, et al. Prediction of tumor recurrence in patients with non-gastric gastrointestinal stromal tumors following resection according to the modified National Institutes of Health criteria. Intest Res. 2014; 12:229–235.

4. von Mehren M, Benjamin RS, Bui MM, et al. Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012; 10:951–960. PMID: 22878820.

5. Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012; 307:1265–1272. PMID: 22453568.

6. Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009; 373:1097–1104. PMID: 19303137.